Nanotechnology Now - Press Release: Neopharma announces expansion into biotechnology and nanotechnology-based research and development

Home > Press > Neopharma announces expansion into biotechnology and nanotechnology-based research and development

At the groundbreaking ceremony for the new facilities for biotechnology and nanotechnology-based research and manufacturing capabilities.

Abstract:
Neopharma, the Abu Dhabi-based pharmaceuticals manufacturer, announced a large scale expansion programme to enter into biotechnology and nanotechnology-based research and manufacturing capabilities.

Neopharma announces expansion into biotechnology and nanotechnology-based research and development

Abu Dhabi, UAE | Posted on October 5th, 2009

The announcement came at a press conference held concurrently with the groundbreaking ceremony for the new facilities. The events were held under the patronage and in the presence of His Highness Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister for Higher Education and Scientific Research, and Chairman of Neopharma.

Elaborating on the series of new expansions, His Excellency Abdullah Humaid Al Mazroei, Vice-Chairman, and Dr. B R Shetty, Managing Director and CEO, Neopharma, said the new facilities will form an integral part of the company's horizontal integration process to produce additional pharmaceutical dosage forms and mark its foray into high-technology based research and development (R&D).

Neopharma's new plants will facilitate the manufacture of nutraceuticals, injectable preparations, topical applications, ophthalmic products and aerosols. In addition, manufacturing lines are being set up for an important group of antibiotic drugs called 'cephalosporins'. Such plants call for dedicated facilities and Neopharma has allocated separate areas for both oral and injectable variations.

With an investment outlay of AED250 million, the new facilities will be designed on the guidelines recommended by the US FDA. Equipments for the expansion are being sourced from the best-in-class companies worldwide and commercial production is expected to begin within 14 months.

Dr. B. R. Shetty said:

"Companies across the globe are reluctant to start new initiatives due to the impact of recession. Yet, at Neopharma, we have been aggressively pressing ahead with our organic growth initiatives that remain crucial to the future of the company. The immense support of Bank of Baroda, the lead financing partner in this project, is a significant stimulus that complements our efforts."

"The success of pharmaceutical companies depends to a large extent on the ability to introduce new and novel therapies. We believe our investments in this area will provide the necessary impetus for sustainable growth."

Dr. Shetty added: "Businesses must adopt the organic route to improve and sustain the nation's manufacturing capabilities. This is our social responsibility - to create, develop and sustain the economic foundation for the good of future generations."

Operating in a competitive generic marketing space, Neopharma has differentiated itself by offering innovative drugs through the in-house research for formulations or through landmark joint venture partnerships that have propelled the company to new heights.

Neopharma's in-house R&D efforts saw the introduction of products in sustained release formats and includes medications for diabetes and the management of angina. The joint venture with biotechnology major Biocon heralded the introduction of a novel nanotech-based oncology product Abraxane that is used in the treatment of breast cancer.

Last week, the company received approval for the manufacture of BR Flu - Oseltamivir for the treatment of H1N1 infections. The product is an outcome of its joint venture with the pharma major Hetero Drugs and the entire range of formulations are expected to be ready shortly.

The new initiatives are expected to help the company obtain an early lead in nanotechnology based devices. With parallel work already initiated, Neopharma will be the first company to start filing patents for such devices.

In addition, Neopharma's state-of-the-art facilities are designed to provide the right training opportunities for students in the country and help create a professional talent pool.

####

About Neopharma
Neopharma is a premier pharmaceuticals manufacturing company based in Abu Dhabi. Set up in October 2003, Neopharma manufactures a wide range of products including antibiotics, analgesics, respiratory medicines, antihistamines, as well as medications for cardiovascular conditions and diabetes.

A robust R&D centre, hi-tech manufacturing and quality embedded operations make the company a manufacturer of world-class pharmaceutical products.

Neopharma has received the prestigious Mohammed bin Rashid Al Maktoum Award in the manufacturing category and is also the recipient of the current European Good Manufacturing Practice Guidelines Certification from Belgium. The company has received the ISO 9001, ISO 14,001 and OHSAS 18,001 certifications for integrated management system encompassing quality, environment and safety standards. These accolades reflect Neopharma's penchant for quality - a key driver for generic pharmaceutical business.

Steered under the visionary leadership of the Board of Directors and Dr. B.R. Shetty, Neopharma is all set to make a foray into the healthcare of the future - biotechnology and nanotechnology based products

For more information, please click here

Contacts:
Zeba Ahmad
JiWin
Tel: +9714 361 3590 (direct)
+9714 361 3333 (switchboard)
Fax: +9714 388 8001

Hammam Alyazji
JiWin
Direct: +9714 3755877

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: